Role of IgE in bullous pemphigoid: A review and rationale for IgE directed therapies

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 3, 2012, Pages 251-257

  Messingham, K N ^a   Pietras, T A ^a   Fairley, J A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Veterans Administration   (United States)

Author keywords

Autoantibodies; Pemphigoid, bullous; Receptors, IgE

Indexed keywords

BP180 PROTEIN; BULLOUS PEMPHIGOID ANTIGEN 1; FC EPSI RI PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN E; MEMBRANE PROTEIN; OMALIZUMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; BULLOUS PEMPHIGOID; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENT CELL; MAST CELL; PATHOGENESIS; REVIEW;

EID: 84864775807     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WL, Lever WF. Basement zone antibodies in bullous pemphigoid. JAMA 1967;200:751-6.
2. Mutasim DF, Takahashi Y, Labib RS, Anhalt GJ, Patel HP, Diaz LA. A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. J Invest Dermatol 1985;84:47-53. (Pubitemid 15186224)
3. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993;151:5742-50. (Pubitemid 23332383)
4. Gaucherand M, Nicolas JF, Paranhos Baccala G, Rouault JP, Reano A, Magaud JP et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein. Evidence using a 55 kDa recombinant protein. Br J Dermatol 1995;132:190-6.
5. Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000;42:577-83. (Pubitemid 30479879)
6. Dimson OG, Giudice GJ, Fu CL, Van den Bergh F, Warren SJ, Janson MM et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003;120:784-8. (Pubitemid 36529079)
7. Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 2005;125:467-72.
8. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007;127:2605-11. (Pubitemid 47585071)
9. Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007;127:1167-74. (Pubitemid 46625148)
10. Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodeme C, Jullien D et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 2011 [In press].
11. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009;123:704-5.
12. Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974;110:378-81.
13. Bowszyc-Dmochowska M, Silny W, Dmochowski M. Detection of IgG4 deposits using a single-step direct immunofluorescence on natrium chloride-separated skin and elevated levels of serum total IgE in active bullous pemphigoid. Journal of Investigative Dermatology 2000;114:804a.
14. Provost TT, Tomasi TB Jr. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol 1974;18:193-200.
15. Messingham KN, Srikantha R, DeGueme AM, Fairley JA. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. Journal of Immunology 2011;187:553-60.
16. Tsuji-Abe Y, Akiyama M, Yamanaka Y, Kikuchi T, Sato-Matsumura KC, Shimizu H. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005;37:145-9. (Pubitemid 40331924)
17. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000;136:174-8. (Pubitemid 30090755)
18. Arno Y, Ohkawa T, Tatsuta M, Hamada Y, Fujimura T, Katsuoka K et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2001;26:14-8. (Pubitemid 32372650)
19. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997;109:573-9. (Pubitemid 27433604)
20. Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 1995;155:5449-54.
21. Christophoridis S, Budinger L, Borradori L, Hunziker T, Merk HF, Hertl M. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 2000;143:349-55. (Pubitemid 30650404)
22. Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008;144:41-8. (Pubitemid 351159388)
23. Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2008;49:153-61. (Pubitemid 350298745)
24. Messingham KA, Noe MH, Chapman MA, Giudice GJ, Fairley JA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 2009;346:18-25.
25. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-6. (Pubitemid 27007649)
26. Ghohestani RF, Cozzani E, Delaporte E, Nicolas JF, Parodi A, Ciaudy A. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 1998;18:202-9. (Pubitemid 28259126)
27. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007;7:365-78. (Pubitemid 46674486)
28. Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997;100:1256-63. (Pubitemid 27386312)
29. Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA, Werb Z et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001;108:1151-8. (Pubitemid 32995373)
30. Wintroub BU, Mihm MC Jr, Goetzl EJ, Soter NA, Austen KF. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 1978;298:417-21. (Pubitemid 8291361)
31. Dvorak AM, Mihm MC Jr, Osage JE, Kwan TH, Austen KF, Wintroub BU. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol 1982;78:91-101. (Pubitemid 12165736)
32. Inaoki M, Takehara K. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J Dermatol Sci 1998;16:152-7. (Pubitemid 128771613)
33. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000;105:113-23. (Pubitemid 30036393)
34. Dubertret L, Bertaux B, Fosse M, Touraine R. Cellular events leading to blister formation in bullous pemphigoid. Br J Dermatol 1980;103:615-24. (Pubitemid 11199170)
35. Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983;8:648-51. (Pubitemid 13129981)
36. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001;164(8 Pt 2):S6-11.
37. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35:408-16. (Pubitemid 40577231)
38. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med 2009;103:1098-113.
39. Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104:188-96.
40. Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Respir Med 2010;104:1608-17.
41. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71. (Pubitemid 36132730)
42. Rabe KF, Calhoun WJ, Smith N, Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011;66:1142-51.
43. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16. (Pubitemid 40293346)
44. Veiling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohe C. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011;16:407-10.
45. Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez Fernandez R. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 2011 [Epub ahead of print].
46. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73 e1.
47. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:1493-9. (Pubitemid 43795739)
48. Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011;128:210-2.
49. Cox LS. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol 2009;5:4.
50. Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) 2009. 2009 [cited 2012 January, 31]. Available from: http://www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm.